Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Biology-driven targeted therapy of pediatric soft-tissue and bone tumors : current opportunities and future challenges / / edited by Thomas G. P. Grünewald and Simone Fulda
| Biology-driven targeted therapy of pediatric soft-tissue and bone tumors : current opportunities and future challenges / / edited by Thomas G. P. Grünewald and Simone Fulda |
| Autore | Simone Fulda |
| Pubbl/distr/stampa | Frontiers Media SA, 2016 |
| Descrizione fisica | 1 online resource (147 pages) : illustrations, charts; digital, PDF file(s) |
| Collana | Frontiers Research Topics |
| Soggetto topico |
Oncology - Research
Cancer in children - Treatment |
| Soggetto non controllato |
targeted therapy
Translational research Ewing sarcoma Sarcoma pediatric oncology Osteosarcoma Immunotherapy bone tumor Rhabdomyosarcoma epithelioid sarcoma |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910136797703321 |
Simone Fulda
|
||
| Frontiers Media SA, 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Comprehensive cancer care for children and their families : summary of a joint workshop by the Institute of Medicine and the American Cancer Society / / Sharyl J. Nass and Margie Patlak, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine, the National Academies of Sciences, Engineering, Medicine
| Comprehensive cancer care for children and their families : summary of a joint workshop by the Institute of Medicine and the American Cancer Society / / Sharyl J. Nass and Margie Patlak, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine, the National Academies of Sciences, Engineering, Medicine |
| Autore | Nass Sharyl J. |
| Pubbl/distr/stampa | Washington, District of Columbia : , : The National Academies Press, , 2015 |
| Descrizione fisica | 1 online resource (127 pages) : illustrations (some color) |
| Disciplina | 618.92/994 |
| Soggetto topico |
Cancer in children - Treatment
Cancer in children - Patients - Care |
| Soggetto genere / forma | Electronic books. |
| ISBN | 0-309-37442-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910480290303321 |
|
Nass Sharyl J.
|
||
| Washington, District of Columbia : , : The National Academies Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Comprehensive cancer care for children and their families : summary of a joint workshop by the Institute of Medicine and the American Cancer Society / / Sharyl J. Nass and Margie Patlak, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine, the National Academies of Sciences, Engineering, Medicine
| Comprehensive cancer care for children and their families : summary of a joint workshop by the Institute of Medicine and the American Cancer Society / / Sharyl J. Nass and Margie Patlak, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine, the National Academies of Sciences, Engineering, Medicine |
| Autore | Nass Sharyl J. |
| Pubbl/distr/stampa | Washington, District of Columbia : , : The National Academies Press, , 2015 |
| Descrizione fisica | 1 online resource (127 pages) : illustrations (some color) |
| Disciplina | 618.92/994 |
| Soggetto topico |
Cancer in children - Treatment
Cancer in children - Patients - Care |
| ISBN |
0-309-37444-8
0-309-37442-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910797530003321 |
|
Nass Sharyl J.
|
||
| Washington, District of Columbia : , : The National Academies Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Comprehensive cancer care for children and their families : summary of a joint workshop by the Institute of Medicine and the American Cancer Society / / Sharyl J. Nass and Margie Patlak, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine, the National Academies of Sciences, Engineering, Medicine
| Comprehensive cancer care for children and their families : summary of a joint workshop by the Institute of Medicine and the American Cancer Society / / Sharyl J. Nass and Margie Patlak, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine, the National Academies of Sciences, Engineering, Medicine |
| Autore | Nass Sharyl J. |
| Pubbl/distr/stampa | Washington, District of Columbia : , : The National Academies Press, , 2015 |
| Descrizione fisica | 1 online resource (127 pages) : illustrations (some color) |
| Disciplina | 618.92/994 |
| Soggetto topico |
Cancer in children - Treatment
Cancer in children - Patients - Care |
| ISBN |
0-309-37444-8
0-309-37442-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910823529703321 |
|
Nass Sharyl J.
|
||
| Washington, District of Columbia : , : The National Academies Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Late treatment effects and cancer survivor care in the young : from childhood to early adulthood / / JoÌrn D. Beck, Carsten Bokemeyer, Thorsten Langer, editors
| Late treatment effects and cancer survivor care in the young : from childhood to early adulthood / / JoÌrn D. Beck, Carsten Bokemeyer, Thorsten Langer, editors |
| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (VIII, 439 p. 46 illus., 33 illus. in color.) |
| Disciplina | 618.9299406 |
| Soggetto topico |
Cancer in children - Treatment
Oncology Pediatrics |
| ISBN | 3-030-49140-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Cardiotoxicity after Childhood Cancer Treatment -- Chapter 2. Kidney -- Chapter 3. Ototoxicity after Childhood Cancer Treatment -- Chapter 4. Complications in tumour orthopaedics -- Chapter 5. Causes and course of (severe) late effects – GI tract -- Chapter 6. Pulmonary toxicity - Causes and course of (severe) late effects in the Lungs -- Chapter 7. Growth hormone deficiency in adult childhood cancer survivors -- Chapter 8. Endocrine Late Effects – Thyroid Gland -- Chapter 9. Disorders of gonadal and reproductive function in survivors of childhood cancer -- Chapter 10. Fertility protection in childhood, adolescents and young adulthood cancer patients -- Chapter 11. Endocrine Late Effects - Adrenal Gland -- Chapter 12. Pregnancy and Birth -- Chapter 13. Endocrine Late Effects - Obesity and Metabolic Syndrome after Childhood Cancer -- Chapter 14. Subsequent primary cancer after childhood, teenage and young adult cancer -- Chapter 15. Diagnostic of Late Treatment effects: Neuropsychological Short Assessment of Disease- and Treatment-related Intelligence Deficits in Children with Brain Tumors -- Chapter 16. Long-term Positive and Negative Psychosocial Outcomes in Young Childhood Cancer Survivors and their Healthy Peers – Posttraumatic Stress Disorder / Somatoform Disorder -- Chapter 17. Cancer related fatigue -- Chapter 18. Late effects after treatment of acute lymphoblastic leukemia in childhood and adolescence -- Chapter 19. Late effects after treatment of acute myeloic leukemia -- Chapter 20. Side Effects and Sequelae of Treatment for Chronic Myeloid Leukemia in Childhood and Adolescence -- Chapter 21. Late effects after treatment of Non-Hodgkin lymphoma in childhood and adolescents -- Chapter 22. Late effects after treatment of Hodgkin lymphoma -- Chapter 23. Langerhans Cell Histiocytosis -- Chapter 24. Diagnostics and Diagnosis of Late Effects in Childhood Brain Tumour Survivors -- Chapter 25. Late effects in children and adolescents with neuroblastoma -- Chapter 26. Late effects in children and adolescents with nephroblastoma -- Chapter 27. Hepatoblastoma and Hepatocellular Carcinoma -- Chapter 28. Long Term Sequelae after retinoblastoma -- Chapter 29. Late effects in children and adolescents with Ewing Sarcoma -- Chapter 30. Late effects in children and adolescents with osteosarcoma -- Chapter 31. Late effects in children and adolescents with soft tissue sarcoma -- Chapter 32. Potential late effects of rhabdoid tumor therapy -- Chapter 33. Late effects after treatment of malignant endocrine tumors -- Chapter 34. Skin cancer – treatment and implications for the long term follow up -- Chapter 35. Breast Cancer -- Chapter 36. Colorectal carcinoma -- Chapter 37. Genetic predisposition to late effects - pharmacogenomics of cisplatin-induced ototoxicity -- Chapter 38. Physical activity, exercise, and sports -- Chapter 39. Late effects after radiotherapy -- Chapter 40. Long-Term Follow-Up from the Point of View of a Person Affected -- Chapter 41. Networks of Survivorship Care. |
| Record Nr. | UNINA-9910483403103321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pediatric cancer therapeutics development / / editors : Jorge DiMartino, Gregory H. Reaman, Franklin O. Smith
| Pediatric cancer therapeutics development / / editors : Jorge DiMartino, Gregory H. Reaman, Franklin O. Smith |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (184 pages) |
| Disciplina | 616.994061 |
| Collana | Pediatric oncology (Series) |
| Soggetto topico |
Cancer - Chemotherapy
Cancer in children - Treatment Drug development |
| ISBN | 3-031-06357-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- 1: History of Drug Development for Children with Cancer -- 1.1 Introduction -- 1.2 Initial Progress -- 1.3 Rise of the Cancer Cooperative Groups -- 1.4 Impact of Regulation to Improve Safety and Efficacy Federal Laws Providing a Regulatory Framework for Drug Development in Children -- 1.5 Indications -- 1.6 Summary -- References -- 2: Targeted Small Molecule Drug Discovery -- 2.1 Introduction -- 2.2 Stage Gating -- 2.3 Phenotypic Drug Discovery -- 2.4 Target-Based Drug Discovery: Considerations for Target Selection/Identification -- 2.5 Target-Based Drug Discovery: Identifying Chemical Starting Points -- 2.6 Hit-to-Lead -- 2.7 Lead Optimization -- 2.8 Candidate Nomination -- References -- 3: An FDA Oncology Perspective of Juvenile Toxicity Studies to Support Pediatric Drug Development -- 3.1 Introduction -- 3.2 Should a JAS Be Considered? -- 3.2.1 ICH S11: Nonclinical Safety Testing in Support of Development of Pediatric Medicines -- 3.2.2 ICH S9: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers -- 3.3 Dinutuximab and Naxitamab -- 3.4 TRK Inhibitors -- 3.5 Conclusion -- References -- 4: Design and Statistical Considerations for Early Phase Clinical Trials in Pediatric Oncology -- 4.1 Introduction -- 4.2 Rule-Based Designs -- 4.2.1 Traditional 3 + 3 Design -- 4.2.2 Accelerated Titration Design -- 4.2.3 Rolling Six Design -- 4.3 Model-Based Designs -- 4.3.1 Continual Reassessment Method (CRM) -- 4.3.2 EWOC and BLRM -- 4.3.3 TITE-CRM and TITE-EWOC -- 4.4 Model-Assisted Designs -- 4.4.1 Modified Toxicity Probability Interval (mTPI) Design -- 4.4.2 Keyboard Design -- 4.4.3 Bayesian Optimal Interval (BOIN) Design -- 4.5 New Designs -- 4.5.1 Modified 4 + 4 Design -- 4.6 Conclusions -- References.
5: Exploratory Clinical Development: From First in Humans to Phase 3 Ready -- 5.1 Introduction -- 5.2 The Therapeutic Hypothesis -- 5.3 Dose and Schedule Determination -- 5.4 Clinical Proof of Concept (PoC) -- 5.5 Putting It All Together: Combined Phase 1-2 Studies -- 5.6 A Role for Pediatric Cancer in Exploratory Drug Development -- References -- 6: Gene and Cell Therapy: How to Build a BioDrug -- 6.1 Introduction -- 6.2 BioDrug ToolKit: Cells -- 6.2.1 Hematopoietic Stem Cells (HSCs) -- 6.2.2 T Lymphocytes -- 6.2.3 Natural Killer (NK) Cells -- 6.2.4 Macrophages (MΦs) -- 6.2.5 Dendritic Cells (DCs) -- 6.2.6 Mesenchymal Stem Cells (MSCs) -- 6.2.7 Human-Induced Pluripotent Stem Cells (iPSCs) -- 6.2.8 Target Tissues -- 6.3 BioDrug ToolKit: Genetic Material and Gene-Editing Machinery -- 6.4 BioDrug ToolKit: Delivery Systems -- 6.4.1 Viral-Based Delivery Systems -- 6.4.2 Nonviral Delivery Systems -- 6.4.2.1 Chemical Methods of Delivery -- 6.4.2.2 Physical Methods of Delivery -- 6.5 Building a BioDrug -- 6.5.1 Building Gene Therapies: Putting Together Genetic Material, Gene-Editing Machinery, Delivery Systems, and Target Cells -- 6.5.2 Building Gene Therapies: Progress and Challenges -- 6.5.3 Building Cell Therapies: Using the BioDrug ToolKit for Treatment of Malignancy -- 6.5.4 Engineered Cell Therapy: Putting Together Cells, Genetic Material, Gene-Editing Machinery, and Delivery Systems to Target Malignant Cells -- 6.5.4.1 Toxicities of Engineered T cell Therapy -- 6.5.4.2 Building a More Effective T cell BioDrug: Remaining Challenges -- 6.6 Summary -- References -- 7: The Pharma/Biotech Model for Drug Development: Implications for Pediatric Cancer Therapeutics -- 7.1 The Old: Large Pharma -- 7.1.1 Background and History -- 7.1.2 Profile of a Large Pharma: Merck & -- Co. -- 7.2 The New: Biotech. 7.2.1 Biotech Financing: From Birth to Adulthood -- 7.3 The Drive for Pharmaceutical Innovation -- 7.4 Current Trends in Pharmaceutical R& -- D -- 7.4.1 Open Innovation -- 7.4.2 Small Entrepreneurial Units -- 7.4.3 Virtualization and Outsourcing -- 7.5 Implications for Pediatric Cancer Therapeutics -- References -- 8: Clinical Research Organizations -- 8.1 Introduction -- 8.2 Business Development -- 8.2.1 CRO Team Members -- 8.2.2 Regulatory Affairs -- 8.2.3 Investigational New Drug (IND)/Investigational Device Exemption (IDE) Application -- 8.2.4 FDA Meetings -- 8.2.5 Investigator's Brochure (IB) -- 8.2.6 Annual Reporting -- 8.2.7 Protocol Development and Amendments -- 8.2.8 Feasibility -- 8.2.9 Study Start-Up -- 8.2.10 Site Activation -- 8.2.11 Determining the Impact on Timelines -- 8.3 Project Management -- 8.3.1 Medical Monitoring -- 8.3.2 Clinical Monitoring -- 8.3.3 Safety -- 8.3.4 Clinical Data Management (CDM) -- 8.3.5 Statistics -- 8.3.6 Quality Assurance -- 8.3.7 Risk Management/Risk Mitigation -- 8.3.8 Recruitment and Retention -- 8.4 Conclusion -- References -- 9: Role of Patients and Advocates in Cancer Therapeutics Development -- 9.1 Introduction and Landscape Perspective -- 9.2 A Brief History and the Rise of Advocate Involvement -- 9.3 Defining the Roles of Patients and Advocates -- 9.4 Policy and Regulatory Issues -- 9.4.1 United States -- 9.4.2 Europe -- 9.4.3 Canada -- 9.4.4 Low- and Middle-Income Countries -- 9.5 Support and Learning for Patient Experts -- 9.6 Involving Patient Experts in the Drug Development Life Cycle -- 9.6.1 Setting Research Priorities and Catalyzing New Ideas -- 9.6.2 Basic and Translational Research -- 9.6.3 Tumor Tissue for Preclinical Testing -- 9.6.4 Philanthropic Funding of Early Drug Development -- 9.6.5 Clinical Trial Design and Ethics Review. 9.6.6 Regulatory Approval and Reimbursement -- 9.6.6.1 FDA -- 9.6.6.2 EMA -- 9.6.6.3 HTAs -- 9.7 Collaboration Among Stakeholders to "ACCELERATE" -- 9.7.1 Pediatric Strategy Forums -- 9.8 Challenges and Opportunities -- 9.9 Recommendations for Academic, Industry, and Regulatory Bodies -- 9.10 Summary and What's Next? -- References -- 10: The Role of Regulatory Agencies in Pediatric Cancer Drug Development -- 10.1 Introduction and History of Legislation Affecting Pediatric Drug Development -- 10.1.1 US Regulatory Programs to Expedite Development of Drugs and Biologics -- 10.1.2 European Regulatory Programs to Expedite Development of Drugs and Biologics -- 10.1.3 US Orphan Drug Program -- 10.2 Regulatory Standards for Approval of Drugs and Biologics -- 10.3 Implementation of Pediatric Regulations (Before FDARA) -- 10.3.1 Implementation of Pediatric Regulations in the United States -- 10.3.2 Legislative Requirements for Pediatric Studies -- 10.3.2.1 United States -- 10.3.2.2 European Union -- 10.3.3 Voluntary Incentive Pediatric Development Programs -- 10.3.3.1 United States -- 10.3.3.2 European Union -- 10.4 Impact of US Pediatric Regulations Prior to FDARA on Pediatric Drug Development -- 10.5 Evolving Regulatory Landscape -- 10.5.1 PREA and the RACE for Children Act -- 10.6 Responding to the Changing Cancer Drug Development Paradigm -- 10.6.1 Evolving Cancer Drug Development -- 10.7 International Multi-Stakeholder Collaboration -- 10.8 Prospects for Future Advances -- References -- 11: Ethical Considerations in Pediatric Cancer Therapeutics Development -- 11.1 Introduction -- 11.2 Ethical Principles Defined by the National Commission and Regulatory Framework for Safeguarding Children Involved in Clinical Investigations. 11.2.1 Additional Safeguards for Children Involved in Clinical Investigations (21 CFR 50, Subpart D) -- 11.3 Interpreting and Applying the Ethical Principles and Regulatory Framework in Pediatric Cancer Therapeutics Development -- 11.3.1 Scientific Necessity and Pediatric Extrapolation -- 11.3.2 Prospect of Direct Benefit in Pediatric Oncology Trials -- 11.3.2.1 Eligibility Criteria: Considerations for the Age of Enrollment -- 11.3.2.2 Early-Phase Pediatric Oncology Trials -- 11.3.2.3 Optimizing Prospect of Direct Benefit: Dose Selection and Study Design in the Era of Molecularly Targeted Products -- 11.3.3 Analysis and Minimization of Risk in Pediatric Oncology Trials -- 11.4 Parental Permission and Child Assent -- 11.5 Conclusions -- References -- 12: Future Directions -- References. |
| Record Nr. | UNINA-9910631099403321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pediatric psycho-oncology : a quick reference on the psychosocial dimensions of cancer symptom management / / edited by Lori Wiener [and five others]
| Pediatric psycho-oncology : a quick reference on the psychosocial dimensions of cancer symptom management / / edited by Lori Wiener [and five others] |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | New York, New York : , : Oxford University Press, , 2015 |
| Descrizione fisica | 1 online resource (433 p.) |
| Disciplina | 618.92/994 |
| Collana | APOS Clinical Reference Handbooks |
| Soggetto topico |
Cancer in children - Psychological aspects
Cancer in children - Treatment |
| Soggetto genere / forma | Electronic books. |
| ISBN |
0-19-933513-3
0-19-939068-1 0-19-933512-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Series; Pediatric Psycho-OncologyA Quick Reference on the Psychosocial Dimensions of Cancer Symptom Management; Copyright; Dedication; Contents; Foreword; Preface; Acknowledgments; Contributors; Introduction; I Cancers of Childhood; 1 Leukemias and Lymphomas; 2 Neuroblastoma; 3 Wilms Tumor; 4 Retinoblastoma; 5 Sarcomas and Other Solid Tumors; 6 Tumors of the Central Nervous System; II Hereditary Cancers; 7 Hereditary Cancer Syndromes; 8 Genetic Counseling for Hereditary Cancer in Childhood; 9 Psychosocial Aspects of Pediatric Hereditary Cancer Syndromes; III Specific Symptom Management
10 Nausea, Vomiting, Anorexia, and Fatigue11 Pain; 12 Anxiety and Depression; 13 Fertility and Sexuality; 14 Psychiatric Emergencies; IV Treatment Issues and Interventions; 15 Medical Aspects of Transplantation; 16 Psychosocial Issues for Transplant Patients and Donors; 17 Medication Adherence; 18 Cognitive Sequelae of Cancer Treatment; 19 Psychotherapeutic Interventions; 20 Electronic Interventions; 21 Integrative Oncology; V Communication and Supportive Care Considerations; 22 Talking to Children and Adolescents about Cancer; 23 Coping with Pediatric Cancer 24 Impact of Cancer on Family and Siblings25 Special Considerations in Working with Families; 26 Spiritual and Religious Considerations; 27 School and Peer Relationships; 28 School and Academic Planning; 29 Ethical Issues in Pediatric Oncology; VI Special Issues in Pediatric Oncology; 30 Integrating Palliative Care; 31 Caring for International Patients; 32 Social Media and Health Care; 33 Pediatric Cancer Survivors: Moving Beyond Cure; Appendix: Health-related Quality of Life in Pediatric Oncology; Index |
| Record Nr. | UNINA-9910459711503321 |
| New York, New York : , : Oxford University Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pediatric psycho-oncology : a quick reference on the psychosocial dimensions of cancer symptom management / / edited by Lori Wiener [and five others]
| Pediatric psycho-oncology : a quick reference on the psychosocial dimensions of cancer symptom management / / edited by Lori Wiener [and five others] |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | New York, New York : , : Oxford University Press, , 2015 |
| Descrizione fisica | 1 online resource (433 p.) |
| Disciplina | 618.92/994 |
| Collana | APOS Clinical Reference Handbooks |
| Soggetto topico |
Cancer in children - Psychological aspects
Cancer in children - Treatment |
| ISBN |
0-19-933513-3
0-19-939068-1 0-19-933512-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Series; Pediatric Psycho-OncologyA Quick Reference on the Psychosocial Dimensions of Cancer Symptom Management; Copyright; Dedication; Contents; Foreword; Preface; Acknowledgments; Contributors; Introduction; I Cancers of Childhood; 1 Leukemias and Lymphomas; 2 Neuroblastoma; 3 Wilms Tumor; 4 Retinoblastoma; 5 Sarcomas and Other Solid Tumors; 6 Tumors of the Central Nervous System; II Hereditary Cancers; 7 Hereditary Cancer Syndromes; 8 Genetic Counseling for Hereditary Cancer in Childhood; 9 Psychosocial Aspects of Pediatric Hereditary Cancer Syndromes; III Specific Symptom Management
10 Nausea, Vomiting, Anorexia, and Fatigue11 Pain; 12 Anxiety and Depression; 13 Fertility and Sexuality; 14 Psychiatric Emergencies; IV Treatment Issues and Interventions; 15 Medical Aspects of Transplantation; 16 Psychosocial Issues for Transplant Patients and Donors; 17 Medication Adherence; 18 Cognitive Sequelae of Cancer Treatment; 19 Psychotherapeutic Interventions; 20 Electronic Interventions; 21 Integrative Oncology; V Communication and Supportive Care Considerations; 22 Talking to Children and Adolescents about Cancer; 23 Coping with Pediatric Cancer 24 Impact of Cancer on Family and Siblings25 Special Considerations in Working with Families; 26 Spiritual and Religious Considerations; 27 School and Peer Relationships; 28 School and Academic Planning; 29 Ethical Issues in Pediatric Oncology; VI Special Issues in Pediatric Oncology; 30 Integrating Palliative Care; 31 Caring for International Patients; 32 Social Media and Health Care; 33 Pediatric Cancer Survivors: Moving Beyond Cure; Appendix: Health-related Quality of Life in Pediatric Oncology; Index |
| Record Nr. | UNINA-9910787225003321 |
| New York, New York : , : Oxford University Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pediatric psycho-oncology : a quick reference on the psychosocial dimensions of cancer symptom management / / edited by Lori Wiener [and five others]
| Pediatric psycho-oncology : a quick reference on the psychosocial dimensions of cancer symptom management / / edited by Lori Wiener [and five others] |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | New York, New York : , : Oxford University Press, , 2015 |
| Descrizione fisica | 1 online resource (433 p.) |
| Disciplina | 618.92/994 |
| Collana | APOS Clinical Reference Handbooks |
| Soggetto topico |
Cancer in children - Psychological aspects
Cancer in children - Treatment |
| ISBN |
0-19-933513-3
0-19-939068-1 0-19-933512-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Series; Pediatric Psycho-OncologyA Quick Reference on the Psychosocial Dimensions of Cancer Symptom Management; Copyright; Dedication; Contents; Foreword; Preface; Acknowledgments; Contributors; Introduction; I Cancers of Childhood; 1 Leukemias and Lymphomas; 2 Neuroblastoma; 3 Wilms Tumor; 4 Retinoblastoma; 5 Sarcomas and Other Solid Tumors; 6 Tumors of the Central Nervous System; II Hereditary Cancers; 7 Hereditary Cancer Syndromes; 8 Genetic Counseling for Hereditary Cancer in Childhood; 9 Psychosocial Aspects of Pediatric Hereditary Cancer Syndromes; III Specific Symptom Management
10 Nausea, Vomiting, Anorexia, and Fatigue11 Pain; 12 Anxiety and Depression; 13 Fertility and Sexuality; 14 Psychiatric Emergencies; IV Treatment Issues and Interventions; 15 Medical Aspects of Transplantation; 16 Psychosocial Issues for Transplant Patients and Donors; 17 Medication Adherence; 18 Cognitive Sequelae of Cancer Treatment; 19 Psychotherapeutic Interventions; 20 Electronic Interventions; 21 Integrative Oncology; V Communication and Supportive Care Considerations; 22 Talking to Children and Adolescents about Cancer; 23 Coping with Pediatric Cancer 24 Impact of Cancer on Family and Siblings25 Special Considerations in Working with Families; 26 Spiritual and Religious Considerations; 27 School and Peer Relationships; 28 School and Academic Planning; 29 Ethical Issues in Pediatric Oncology; VI Special Issues in Pediatric Oncology; 30 Integrating Palliative Care; 31 Caring for International Patients; 32 Social Media and Health Care; 33 Pediatric Cancer Survivors: Moving Beyond Cure; Appendix: Health-related Quality of Life in Pediatric Oncology; Index |
| Record Nr. | UNINA-9910819303803321 |
| New York, New York : , : Oxford University Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
